Blair William & Co. IL lowered its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) by 2.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 50,074 shares of the company’s stock after selling 1,000 shares during the quarter. Blair William & Co. IL’s holdings in Elanco Animal Health were worth $815,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds have also modified their holdings of ELAN. Jones Financial Companies Lllp acquired a new stake in Elanco Animal Health in the fourth quarter valued at approximately $37,000. Tower Research Capital LLC TRC raised its holdings in shares of Elanco Animal Health by 169.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,212 shares of the company’s stock valued at $93,000 after purchasing an additional 3,906 shares in the last quarter. Capstone Investment Advisors LLC purchased a new stake in shares of Elanco Animal Health during the 1st quarter worth $167,000. HBK Sorce Advisory LLC acquired a new position in shares of Elanco Animal Health during the fourth quarter worth $169,000. Finally, Atomi Financial Group Inc. purchased a new position in Elanco Animal Health in the first quarter valued at $180,000. 97.48% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity at Elanco Animal Health
In related news, Director William F. Doyle acquired 15,000 shares of Elanco Animal Health stock in a transaction that occurred on Tuesday, May 21st. The stock was purchased at an average price of $16.98 per share, for a total transaction of $254,700.00. Following the completion of the purchase, the director now directly owns 76,330 shares of the company’s stock, valued at $1,296,083.40. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. 0.57% of the stock is currently owned by insiders.
Analysts Set New Price Targets
A number of brokerages have issued reports on ELAN. Barclays decreased their price target on Elanco Animal Health from $23.00 to $21.00 and set an “overweight” rating for the company in a report on Friday, June 28th. Piper Sandler lowered their price target on Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating for the company in a report on Monday, July 1st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, Elanco Animal Health has a consensus rating of “Moderate Buy” and an average target price of $17.57.
Read Our Latest Analysis on ELAN
Elanco Animal Health Price Performance
Shares of NYSE ELAN opened at $12.79 on Tuesday. The business has a 50-day moving average price of $16.21 and a 200 day moving average price of $15.61. The company has a debt-to-equity ratio of 0.95, a current ratio of 3.29 and a quick ratio of 1.96. Elanco Animal Health Incorporated has a 52-week low of $8.52 and a 52-week high of $18.80.
Elanco Animal Health (NYSE:ELAN – Get Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.08. The business had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.18 billion. Elanco Animal Health had a positive return on equity of 5.98% and a negative net margin of 29.83%. The company’s revenue was down 4.1% compared to the same quarter last year. During the same period in the prior year, the company earned $0.45 earnings per share. Equities analysts predict that Elanco Animal Health Incorporated will post 0.93 EPS for the current year.
About Elanco Animal Health
(Free Report)
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.
Featured Stories
Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN – Free Report).
Receive News & Ratings for Elanco Animal Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Elanco Animal Health and related companies with MarketBeat.com’s FREE daily email newsletter.